Actively Recruiting
Influence of Glucose on Metabolism and Clinical Symptoms of Patients With Parkinson's Disease
Led by University Hospital Schleswig-Holstein · Updated on 2025-09-22
50
Participants Needed
1
Research Sites
117 weeks
Total Duration
On this page
Sponsors
U
University Hospital Schleswig-Holstein
Lead Sponsor
U
University of Kiel
Collaborating Sponsor
AI-Summary
What this Trial Is About
Many patients with Parkinson's Disease (PD) report an increased consumption of fast-acting sugars. This tendency to consume sweet, high-sugar foods occurs in some patients even before the onset of cardinal motor symptoms. Some recent studies have demonstrated that PD patients have an increased consumption of fast-acting carbohydrates compared to healthy controls. However, the reason for this change in eating behavior has not yet been adequately explained. It is discussed that the increased sugar intake leads to an increased dopamine release in the brain via an increase in insulin and thus to an improvement in clinical symptoms. This study investigates the influence of fast-acting carbohydrates on insulin and glucose blood levels as well as motor and non-motor symptoms in patients with PD using an oral glucose tolerance test and a placebo oral glucose tolerance test in a crossover design.
CONDITIONS
Official Title
Influence of Glucose on Metabolism and Clinical Symptoms of Patients With Parkinson's Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of Parkinson's Disease, stage Hoehn & Yahr 1.5-3
- Ability to pause antiparkinsonian medication in the morning without relevant impairment
- Capacity to give consent (determined in doubt by two independent neurologists, MOCA 6518) and written informed consent
- Patients are between 50 and 80 years of age, with exceptions for a maximum of 5 additional patients enrolled per group
- Completion of a 3-day dietary protocol for stratification into patients with and without sweet craving
- Group I: increased hunger for sweets
- Group II: no increased hunger for sweets
You will not qualify if you...
- Other significant neurological diseases primarily affecting the central nervous system (e.g., multiple sclerosis)
- Diagnosis of diabetes mellitus or prediabetes
- Use of medications that affect glucose metabolism, including antidiabetics, glucocorticoids, ciclosporin, tacrolimus, sirolimus, beta-blockers, thiazide diuretics, beta-2 adrenoreceptor agonists, theophylline, Clozapine, olanzapine, paliperidone, quetiapine, risperidone, tricyclic antidepressants, mirtazapine, mianserin, carbamazepine, gabapentin, pregabalin, valproic acid, lithium, antiretroviral drugs, statins
- Presence of cardiac or brain pacemakers
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department for Neurology, University of Kiel
Kiel, Germany, 24118
Actively Recruiting
Research Team
E
Eva Schäffer, MD
CONTACT
J
Julienne Haas, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here